Arm Holdings plc (ARM)
Verdict history · ARM
Every call Verdix has made on ARM.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
See methodology for how verdicts are produced. Full track record →
Why the panel isn’t ready to call ARM yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NASDAQ · Information Technology / Semiconductor IP · 2026-08-08 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitMEDIUM confidence
Why
A panel of five investing frameworks dissects ARM Holdings at $282.57, where a dominant semiconductor-IP moat and 20%+ revenue growth collide with extreme multiples — 100x forward P/E, 50x sales — and a CEO-CFO guidance gap. One voice sees a disruptive buying opportunity; three urge waiting for a better price; one warns the earnings themselves may be an SBC-fueled illusion. The verdict: WAIT — the business is exceptional, but the price demands a pullback or a confirmed re-acceleration before committing capital.Level to watch
Key support 276.36−2.2% from 282.57
Next catalyst
Trigger to confirm the breakout: A weekly close above $298 on expanding volume would signal re-acceleration, flipping the WAIT to a BUY for price/timing-cautious panelists by demonstrating the uptrend is intact above the key 38.2% Fibonacci retracement.The panel's take
Verdict: WAIT · Conviction: MED · Last price: 282.57
The BUY-vs-WAIT split dominates: The Disruptive-Innovation Seeker (Bullish) sees a buying opportunity now at $283, while the technical scout and The Intrinsic-Value Modeler both love the business but want a lower entry — a pure PRICE/TIMING objection, not a BUSINESS objection. The GARP Operator's objection is also PRICE/TIMING (PEG too high, not the company). The Forensic Skeptic's objection is a genuine BUSINESS objection (SBC dilution, credibility gap, valuation as structural). With 1 Bullish voice and 3 cautious voices — 2 of which explicitly say 'great business, wrong price' — the structure is BUY vs WAIT, not BUY vs SELL. HOLD would misclassify this as business-level disagreement when the dominant cautious objection is price. The The Intrinsic-Value Modeler-identified entry zone ($150-180, or the technical scout's $249-250 pullback) provides a specific lower-price trigger, fulfilling the WAIT criteria.
Key levels
Key levels · ARM
USD · as of 2026-08-08Analyst consensus target 282.57 USD · range 282.57–282.57
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran Arm Holdings plc past a panel of 5 legendary investors' frameworks.
The panel · 5 investors
The Disruptive-Innovation SeekerDisruptive Innovation🟢 BullishMed
Signal: Sees ARM as the foundational architecture for the AI silicon revolution, where the shift to v9 architecture doubles royalty rates and the $2B AGI CPU backlog signals an early-adoption S-curve that could drive revenue at a 30-35% CAGR — making short-term supply chain bottlenecks a buying opportunity, not a thesis breaker. Conviction: Conviction is reinforced by multiple independent drivers — v9 royalty doubling, data center share gains from under 5% to a potential 20-30%, and edge AI expansion into robotics and autonomous systems — all pointing to a $600 base-case target that compresses the forward P/E to roughly 25x within five years.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: Acknowledges ARM's exceptional business model — 94% gross margins, net cash, genuine switching costs — but a 245x trailing P/E and 221x EV/EBITDA mean the market has already priced in a decade of perfection, with base-case DCF value landing at $190-220 per share, 22-33% below the current price. Conviction: Conviction is held back by one contested assumption: the bull case requires 25%+ revenue growth for 10 years and 45% operating margins, yet smartphone revenue is mature, data center share is still small, and the CEO-CFO guidance gap on AGI CPU demand suggests the growth trajectory is less certain than the price implies.
The Scuttlebutt Growth InvestorGrowth/Management⚫ NeutralMed
Signal: Scores ARM 13 out of 15 on the Fisher checklist — insurmountable switching costs, v9 royalty uplift, and a capable management team — but the stock's 100x forward earnings and 38x forward revenue leave zero margin for safety, and insider selling by multiple executives in June 2026 is a yellow flag that tempers what would otherwise be a textbook long-term compounder. Conviction: Conviction is held back by a single contested dependency: the valuation is so extreme that even a minor disappointment — a supply-chain miss, a customer defection, or a RISC-V foothold — could trigger a severe re-rating, making a better entry the prudent course despite the business's exceptional quality.
The GARP OperatorGrowth (GARP)🔴 BearishMed
Signal: Identifies ARM as a textbook fast-grower with a superb business — 95% gross margins, net cash, and an insurmountable moat — but the PEG ratio of 2.82 means investors are paying $2.82 for every dollar of expected growth, more than double the The GARP Operator threshold of 1.0, and insiders are selling, not buying. Conviction: Conviction is held back by one undisputed fact: at a 245x trailing P/E, the stock is already pricing in flawless execution; combined with persistent insider selling and the CEO-CFO $1B guidance gap, there is simply no margin of safety at current levels.
The Forensic SkepticContrarian/Forensic🔴 BearishMed
Signal: Recognizes ARM's genuine moat but argues stock-based compensation exceeds net income, making reported GAAP profitability an optical illusion while insider selling confirms management is monetizing shares at inflated levels — his normalized intrinsic value lands at $40-60, implying a negative 528% margin of safety. Conviction: Conviction is reinforced by multiple independent red flags: SBC running above $600M annually versus $904M net income, a negative buyback yield of -0.66%, the CEO's $2B demand claim contradicted by the CFO's $1B official guide, and heavy insider selling with zero insider buys — a pattern The Forensic Skeptic's framework treats as irreconcilable with a buy case at any price above normalized value.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- ARM possesses one of the widest economic moats in technology, with 99% smartphone share, 94-95% gross margins, and genuine switching costs that lock in customers across design cycles.
- Revenue growth is accelerating at 20%+ driven by the v9 architecture transition and AI data center expansion — the top-line story is real and broadly agreed upon.
- The supply chain bottleneck — specifically TSMC capacity — is real, unresolved, and creates a credibility gap between the CEO's $2B AGI CPU aspiration and the CFO's $1B official guidance.
- Insider selling at elevated prices, with multiple executives selling in June 2026 and zero insider buys, is a cautionary signal every panelist acknowledges.
- The stock trades at extreme multiples — 100x+ forward P/E, 50x sales, 221x EV/EBITDA — that leave no room for execution missteps regardless of one's view on fair value.
The real debate
- The Disruptive-Innovation Seeker sees the supply-chain bottleneck as a temporary buying opportunity comparable to Tesla's production-hell era, while the Forensic Skeptic views the CEO-CFO guidance gap as a structural credibility problem signaling that management is talking their book to prop up the stock.
- The Intrinsic-Value Modeler and the GARP Operator both want a lower entry but disagree on what constitutes fair value: the DCF lands at $190-220 (a 22-33% discount to current), while the PEG framework would require a pullback toward $150-180 for a PEG near 1.0.
- The Forensic Skeptic's normalized intrinsic value of $40-60 is an order of magnitude below every other panelist, creating the deepest tension: is the market merely overpaying for quality, or is the entire reported earnings base an SBC-inflated illusion that masks true per-share economics?
The question it comes down to: Can ARM's royalty-revenue engine grow fast enough — and can management secure enough TSMC capacity — to compress today's extreme multiples before the stock re-rates the hard way?
The bottom line
- Trigger to confirm the breakout: A weekly close above $298 on expanding volume would signal re-acceleration, flipping the WAIT to a BUY for price/timing-cautious panelists by demonstrating the uptrend is intact above the key 38.2% Fibonacci retracement.
- Key accumulation zone: A pullback into $185-220 — the Intrinsic-Value Modeler's base-case DCF range — or a retest of $249-250 would trigger higher-conviction entry for multiple panelists who love the business but refuse to pay today's multiples.
- Risk to monitor: A weekly close below $250 combined with an earnings miss or guidance cut would validate the Forensic Skeptic's BUSINESS objection, confirming the supply-chain bottleneck is structural rather than temporary and signaling the Stage 2 uptrend is breaking.
- Next catalyst: Management explicitly raising official AGI CPU revenue guidance above $2B with a confirmed TSMC capacity commitment would resolve the CEO-CFO credibility gap and force a re-evaluation of the growth trajectory across the panel.
- Further out: A major cloud provider announcing a non-ARM CPU architecture for AI inference workloads would break the design-win flywheel and threaten the Disruptive-Innovation Seeker's thesis that ARM's data center share is on an irreversible S-curve.
contact@verdixhq.com · Published 2026-08-08 · Prices as of 2026-08-08 · Time horizon: 3–12 months · No direct position held in ARM · ARM verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated